C Dean Schell

They say he twittered his life away...

[Dr. Pat Soon-Shiong @DrPatrick]

What an honor to meet with President Erdogan today. Under his leadership Turkey will be the center of excellence for patients with cancer in the region.

[Dr. Pat Soon-Shiong @DrPatrick]

Neoepitope vaccine development - the sequence and orchestration of the NK cell and T cell for a durable response with Neoepitope vaccine is important. IL-15 and NHS-IL-12 and Adeno vaccine are key players. Our 2019 paper.

[C Dean Schell @Dean_Schell]

@realDonaldTrump Reasoning Engines. Reasoning Machines. Language Reasoning Engines. Whatever it is we need to stop calling them things that over humanize them. They are semi-autonomous tools.

[Dr. Pat Soon-Shiong @DrPatrick]

What a forward looking organization @Aetna! Congratulations on addressing the administrative burden of doctors looking after patients with cancer and instituting a modernized oncology prior authorization system.

The potential for patients and their doctors accessing state of the art clinical trials as a "trial match" is now real.

https://t.co/xDMNut4KVu

[C Dean Schell @Dean_Schell]

@DrPatrick @ImmunityBio Keep pressing, Doc. I lost another friend to cancer this past week. Never let up.

[Dr. Pat Soon-Shiong @DrPatrick]

Our @ImmunityBio team is having great reception at World Conference Lung Cancer (WCLC26) in Seoul Korea discussing ReQ201A-NSCLC (Phase 3).

The world is waking up to the fact that ALC (absolute lymphocyte count) and Natural Killer (NK) cells matter to prolong life. The conclusion from the Chudzik abstract is consistent with what we saw in QUILT-3.055

https://t.co/WOe5Chw2sW

Abstract: P3.175: Peripheral Blood Immunophenotyping Reveals Patterns of Short and Durable Immunotherapy Response in NSCLC. Robert Chudzik et al., 2026

[Dr. Pat Soon-Shiong @DrPatrick]

The most precise cancer target ever discovered is not a drug company's molecule. It is the neoepitope... The mutation only your tumor carries, invisible to normal cells. Find it and present it. Let the immune system do what it was evolved to do. Our cancer moonshot coming to fruition.

[Dr. Pat Soon-Shiong @DrPatrick]

Wow
Please be aware this is a total scam !!!

[C Dean Schell @Dean_Schell]

@DrPatrick @latimes Move to Alabama, @DrPatrick ! I’m telling’ ya. It’s just right and we are ready to help you conquer cancer worldwide! Going Long! Hanging tough! Never quit! Never yield!

[Dr. Pat Soon-Shiong @DrPatrick]

Architect of billionaire tax tried to ‘extort’ support for the measure and targeted women, union reports find ⁦@latimes⁩ https://t.co/WqVjWR0ycE

[Dr. Pat Soon-Shiong @DrPatrick]

The biology is consistent. IL-15 and IL-12 are key to persistence of CAR-T cells. The next evolution. Solid tumors.

[Dr. Pat Soon-Shiong @DrPatrick]

Connecting the dots on discovering neoepitopes and our work on the cancer vaccine, over a decade quest Dot #1 Both Forbes and 60 Minutes highlighted our work in 2014 and 2015. Not many understood where we were going with this 47 second computer analysis of the tumor genome to discover what is now known as "Neoepitopes", the personalized antigen targets on the tumor. Until we could accomplish that fundamental science, nothing else matters. The efforts were met with skepticism but here we are in 2026 and without that AI platform, a vaccine cannot be created! So Dot 1 is the 60 minutes piece and the Forbes article. Now a decade later big Pharma enters the race!

60 Minutes: https://t.co/vrgtM7BPyq

60 MInutes Overtime: https://t.co/V5eZ30WuNj

Forbes: https://t.co/CapXvAdiBB

[Dr. Pat Soon-Shiong @DrPatrick]

Dot #2 The first of many patents covering how to discover the immunogenic peptides necessary for a personalized cancer vaccine filed in 2015. Now cited by over 160 patent applications.

https://t.co/CYopFWVpjo

[Dr. Pat Soon-Shiong @DrPatrick]

Dot #2

The first of many patents covering how to discover the immunogenic peptides necessary for a personalized cancer vaccine filed in 2015. Now cited by over 160 patent applications.

https://t.co/CYopFWVpjo

[Dr. Pat Soon-Shiong @DrPatrick]

Exciting to see that finally that big pharma has woken to the race to find a cancer vaccine. What is needed is the PERSONALIZED mutations that make up the components of that vaccine…and we began that quest since 2015 at NANTOMICS!
Now the fundamental computing methods have been established and tons of IP claims have been issued…connecting the dots on the NANT CANCER VACCINE .. a decade of work coming to fruition!
Will send a flow of connecting Nant dots next. In the meantime go to https://t.co/DB84nbanQI and look under publications….patents coming next

[Dr. Pat Soon-Shiong @DrPatrick]

This Is the Biggest Obstacle to New Cancer Cures https://t.co/A1ft8bpU9F via @NYTOpinion

[Dr. Pat Soon-Shiong @DrPatrick]

Pleased to see the fruits of our ongoing clinical trials in patients with colon cancer and the goal to reduce the risk of the cancer coming back.

The goal to prevent colon cancer is even more challenging - a cancer vaccine. Our NCI sponsored trial has taken on this challenge - a TriAd vaccine plus Anktiva. https://t.co/88NoAkkJnK
This cancer vaccine trial in patients with a high risk of developing colon cancer has now been fully accrued and one year mark has passed. The combination of Anktiva + vaccine against CEA, MUC1, and brachyury represents our first cancer vaccine trial. This time next year is when the second anniversary of the vaccine is evaluated.

[ANKTIVA @GetAnktivanow]

@DrPatrick

[Dr. Pat Soon-Shiong @DrPatrick]

Proud moment for our team and for patients across Europe.

Our first EU (German) labeling and packaging run for ANKTIVA is complete. These vials represent more than manufacturing. They mark the next step in bringing this IL-15 immunotherapy to patients with BCG-unresponsive NMIBC who previously faced limited options.

Global access continues. Unstoppable

[C Dean Schell @Dean_Schell]

@GretchMick @ImmunityBio That’s awesome! All the best!